A Lab Mistake at Cambridge Reveals a Powerful New Way to Modify Drug Molecules

By Curie

A failed control experiment at the University of Cambridge has led to a discovery that could change how pharmaceutical companies design drugs — using light instead of toxic chemicals to modify complex molecules at the final stages of development.

The technique, published March 12 in Nature Synthesis, is what the researchers call an "anti-Friedel-Crafts" reaction. Traditional methods for forming carbon-carbon bonds — the chemical backbone of drug molecules — require harsh conditions, metal catalysts, and toxic reagents. Those reactions typically happen early in drug manufacturing, with chemists then spending months adding more steps to reach the final medicine.

The Cambridge approach flips that. An LED lamp triggers a self-sustaining chain reaction at room temperature, creating carbon-carbon bonds under mild conditions without expensive or dangerous chemicals.

"We've found a new way to make precise changes to complex drug molecules, particularly ones that have been exceptionally difficult to modify in the past," said David Vahey, a PhD researcher at St John's College, Cambridge, and first author of the study. "Scientists can spend months rebuilding large parts of a molecule just to test one small change. Now, instead of doing a multistep process for hundreds of molecules, scientists can start with their hit and make small modifications later on."

The discovery was accidental. Vahey was testing a photocatalyst during a control experiment when he removed it — and found the reaction worked just as well, sometimes better, without it. Most researchers would have dismissed the result as a failed control. Instead, he chose to investigate.

"Failure after failure, then we found something we weren't expecting in the mess — a real diamond in the rough," Vahey said. "And it is all thanks to a failed control experiment."

The team collaborated with AstraZeneca to test whether the technique could meet real-world manufacturing requirements. They also used machine learning models, developed with Trinity College Dublin, to predict where the reaction would work on entirely new molecules.

The implications extend beyond drug discovery. By reducing synthesis steps, the method cuts chemical waste, energy consumption, and manufacturing time — increasingly important as the pharmaceutical industry faces pressure to reduce its environmental footprint.

"Transitioning the chemical industry to a sustainable industry is arguably one of the most difficult parts of the whole energy transition," said Professor Erwin Reisner, who led the research group. "This is a new way to make a fundamental carbon-carbon bond, and that's why the potential impact is so great."